Albireo Pharma is a commercial-stage biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Co.'s product pipeline includes: Bylvay, which is approved in the U.S. and Europe for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its primary candidate for the treatment of adult liver diseases; and A2342, its primary preclinical candidate for the treatment of adult viral and liver diseases.
|
Free ALBO Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (2.57 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: ALBO Stock Forecast Based on Zacks ABR data; powered by Xignite |